Plasminogen activator inhibitor‐1, inflammation, obesity, insulin resistance and vascular risk

Summary.  Elevated plasma plasminogen activator inhibitor‐1 (PAI‐1) level is a core feature of insulin‐resistance syndrome (IRS). Atherothrombotic complications in IRS are partly attributed to impaired fibrinolysis caused by increased plasma PAI‐1 levels. Although the etiology of IRS is far from being explained, the clustering of inflammation, adipose tissue accumulation and insulin resistance suggests an etiopathological link. Proinflammatory cytokines might regulate PAI‐1 expression in IRS; however, more studies are needed to confirm this complex mechanism in humans. Furthermore, modifying PAI‐1 expression by PAI‐1 inhibitors provides a new challenge and may reveal the true role of PAI‐1 in atherosclerotic and insulin resistance processes.

[1]  D. Richards,et al.  10 YEARS AFTER , 2004, Evidence-Based Dentistry.

[2]  P. Morange,et al.  Plasma PAI-1 Levels Are More Strongly Related to Liver Steatosis Than to Adipose Tissue Accumulation , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[3]  P. Hufnagl,et al.  Direct binding of Nur77/NAK-1 to the plasminogen activator inhibitor 1 (PAI-1) promoter regulates TNF alpha -induced PAI-1 expression. , 2003, Blood.

[4]  K. Jungermann,et al.  Hypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes. , 2003, Blood.

[5]  P. Morange,et al.  Nutritionally Induced Obesity Is Attenuated in Transgenic Mice Overexpressing Plasminogen Activator Inhibitor-1 , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[6]  P. Libby.  Inflammation in atherosclerosis , 2002, Nature.

[7]  Y. Ueta,et al.  Orexin-A augments voltage-gated Ca2+ currents and synergistically increases growth hormone (GH) secretion with GH-releasing hormone in primary cultured ovine somatotropes. , 2002, Endocrinology.

[8]  D. Loskutoff,et al.  Do PAI-1 and vitronectin promote or inhibit neointima formation? The exact role of the fibrinolytic system in vascular remodeling remains uncertain. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[9]  R. Mooney,et al.  Interleukin-6 induces cellular insulin resistance in hepatocytes. , 2002, Diabetes.

[10]  P. Carmeliet,et al.  Plasminogen Activator Inhibitor 1 and Vitronectin Protect Against Stenosis in a Murine Carotid Artery Ligation Model , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[11]  A. Aljada,et al.  A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. , 2002, The American journal of cardiology.

[12]  R. Grimble.  Inflammatory status and insulin resistance , 2002, Current opinion in clinical nutrition and metabolic care.

[13]  D. Bastelica,et al.  Relationships between Fibrinolytic and Inflammatory Parameters in Human Adipose Tissue: Strong Contribution of TNFα Receptors to PAI-1 Levels , 2002, Thrombosis and Haemostasis.

[14]  K. Frayn,et al.  Adipose tissue as a buffer for daily lipid flux , 2002, Diabetologia.

[15]  M. Eren,et al.  Age-Dependent Spontaneous Coronary Arterial Thrombosis in Transgenic Mice That Express a Stable Form of Human Plasminogen Activator Inhibitor-1 , 2002, Circulation.

[16]  F. Stanley,et al.  A Forkhead/Winged Helix-related Transcription Factor Mediates Insulin-increased Plasminogen Activator Inhibitor-1 Gene Transcription* , 2002, The Journal of Biological Chemistry.

[17]  J. Hoover-Plow,et al.  In Vivo Plasminogen Deficiency Reduces Fat Accumulation , 2002, Thrombosis and Haemostasis.

[18]  W. Fay,et al.  Endogenous Vitronectin and Plasminogen Activator Inhibitor-1 Promote Neointima Formation in Murine Carotid Arteries , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[19]  E. Ravussin,et al.  Increased Fat Intake, Impaired Fat Oxidation, and Failure of Fat Cell Proliferation Result in Ectopic Fat Storage, Insulin Resistance, and Type 2 Diabetes Mellitus , 2002, Annals of the New York Academy of Sciences.

[20]  N. Hacohen,et al.  Tumor necrosis factor-α suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: Nuclear factor-κB activation by TNF-α is obligatory , 2002 .

[21]  S. Haffner,et al.  Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. , 2002, Diabetes.

[22]  Haiyan Xu,et al.  Exclusive Action of Transmembrane TNFα in Adipose Tissue Leads to Reduced Adipose Mass and Local But Not Systemic Insulin Resistance. , 2002, Endocrinology.

[23]  A. Aljada,et al.  Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. , 2002, The Journal of clinical endocrinology and metabolism.

[24]  A. Luttun,et al.  Lack of Plasminogen Activator Inhibitor-1 Promotes Growth and Abnormal Matrix Remodeling of Advanced Atherosclerotic Plaques in Apolipoprotein E–Deficient Mice , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[25]  Christian Weyer,et al.  High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. , 2002, Diabetes.

[26]  W. Dietz,et al.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.

[27]  P. Morange,et al.  Stromal Cells Are the Main Plasminogen Activator Inhibitor‐1‐Producing Cells in Human Fat: Evidence of Differences Between Visceral and Subcutaneous Deposits , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[28]  D. Bastelica,et al.  Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss , 2001, Diabetologia.

[29]  D. Dichek,et al.  Plasminogen Activator Inhibitor Type 1 Increases Neointima Formation in Balloon-Injured Rat Carotid Arteries , 2001, Circulation.

[30]  Michael Karin,et al.  Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Ikkβ , 2001, Science.

[31]  F. España,et al.  Plasma PAI-1 Levels in Obese Children – Effect of Weight Loss and Influence of PAI-1 Promoter 4G/5G Genotype , 2001, Thrombosis and Haemostasis.

[32]  G. Shulman,et al.  Prevention of fat-induced insulin resistance by salicylate. , 2001, The Journal of clinical investigation.

[33]  D. Loskutoff,et al.  Disruption of the plasminogen activator inhibitor‐1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  G. Pellegrini,et al.  Plasminogen Activator Inhibitor Type 1 Is Increased in the Arterial Wall of Type II Diabetic Subjects , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[35]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[36]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[37]  Kukin Ml.  The Heart Outcomes Prevention Evaluation Study. , 2001, Current cardiology reports.

[38]  R. Unger,et al.  Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. , 2001, Diabetes.

[39]  J. Pogue,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.

[40]  P. Morange,et al.  Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. , 2000, Diabetes.

[41]  S. Haffner,et al.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.

[42]  P. Grant,et al.  Plasminogen-activator inhibitor type 1 and coronary artery disease. , 2000, The New England journal of medicine.

[43]  H. Hauner,et al.  Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture. , 2000, Metabolism: clinical and experimental.

[44]  B. Sobel,et al.  Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. , 2000, Diabetes.

[45]  P. Morange,et al.  Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[46]  D. Singer,et al.  Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. , 2000, JAMA.

[47]  K. Uysal,et al.  Tumor necrosis factor α is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1 , 1999 .

[48]  M. Cesari,et al.  Plasminogen activator inhibitor type 1 in ischemic cardiomyopathy. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[49]  S. Coppack,et al.  C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[50]  P. Morange,et al.  Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. , 1999, Diabetes.

[51]  J. Sowers,et al.  Diabetes and cardiovascular disease. , 1999, Diabetes care.

[52]  B. Howard,et al.  Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[53]  M. Cigolini,et al.  Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha? , 1999, Atherosclerosis.

[54]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[55]  L. Weinehall,et al.  High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. , 1998, Circulation.

[56]  A. Hamsten,et al.  Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[57]  R. Bergman,et al.  Proinsulin and insulin concentrations in relation to carotid wall thickness: Insulin Resistance Atherosclerosis Study. , 1998, Stroke.

[58]  B. Sobel,et al.  Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. , 1998, Circulation.

[59]  D. Raccah,et al.  Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women , 1998, International Journal of Obesity.

[60]  G. Struhl,et al.  Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb , 1998, Nature.

[61]  B. Seed,et al.  PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.

[62]  J S Yudkin,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-�, in Vivo* , 2022 .

[63]  Margaret S. Wu,et al.  Targeted Disruption of the Tumor Necrosis Factor-α Gene: Metabolic Consequences in Obese and Nonobese Mice , 1997, Diabetes.

[64]  M. Pfeffer,et al.  Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. , 1997, Circulation.

[65]  D. Loskutoff,et al.  The fat mouse: a powerful genetic model to study elevated plasminogen activator inhibitor 1 in obesity/NIDDM. , 1997, Thrombosis and haemostasis.

[66]  P. Morange,et al.  Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular Disease , 1997, Diabetes.

[67]  J. Yudkin,et al.  Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction. , 1997, Atherosclerosis.

[68]  S. Thompson,et al.  Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. , 1996, Circulation.

[69]  M. Muggeo,et al.  Liver Steatosis and Its Relation to Plasma Haemostatic Factors in Apparently Healthy Men - Role of the Metabolic Syndrome , 1996, Thrombosis and Haemostasis.

[70]  S. Yamashita,et al.  Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty , 1996, Nature Medicine.

[71]  G. Dagenais,et al.  Hyperinsulinemia as an independent risk factor for ischemic heart disease. , 1996, The New England journal of medicine.

[72]  G. Targher,et al.  Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[73]  B. Spiegelman,et al.  IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance , 1996, Science.

[74]  M. Stern.  Diabetes and Cardiovascular Disease: The “Common Soil” Hypothesis , 1995, Diabetes.

[75]  B. Sobel,et al.  Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. , 1995, Circulation.

[76]  B. Spiegelman,et al.  Tumor Necrosis Factor α: A Key Component of the Obesity-Diabetes Link , 1994, Diabetes.

[77]  P. Giral,et al.  Relation between Plasminogen Activator Inhibitor-1 and Hepatic Enzyme Concentrations in Hyperlipidemic Patients , 1994, Thrombosis and Haemostasis.

[78]  B. Sobel,et al.  Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[79]  S. Haffner,et al.  Relationship of Proinsulin and Insulin to Cardiovascular Risk Factors in Nondiabetic Subjects , 1993, Diabetes.

[80]  M. Blankenstein,et al.  The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. , 1993, Metabolism: clinical and experimental.

[81]  J. Yudkin,et al.  Effects of Metformin on Insulin Resistance, Risk Factors for Cardiovascular Disease, and Plasminogen Activator Inhibitor in NIDDM Subjects: A study of two ethnic groups , 1993, Diabetes Care.

[82]  M. Alessi,et al.  Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis , 1991, Diabetologia.

[83]  A. Hamsten,et al.  Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. , 1990, Arteriosclerosis.

[84]  P. Vague,et al.  Increased Plasminogen Activator Inhibitor Activity in Non Insulin Dependent Diabetic Patients – Relationship with Plasma Insulin , 1989, Thrombosis and Haemostasis.

[85]  T. Kooistra,et al.  Insulin Stimulates the Synthesis of Plasminogen Activator Inhibitor 1 by the Human Hepatocellular Cell Line Hep G2 , 1988, Thrombosis and Haemostasis.

[86]  J. Auwerx,et al.  Tissue‐Type Plasminogen Activator Antigen and Plasminogen Activator Inhibitor in Diabetes Mellitus , 1988, Arteriosclerosis.

[87]  M. Blombäck,et al.  PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.

[88]  P. Grant,et al.  Hormonal Control of Haemostasis During Hypoglycaemia in Diabetes Mellitus , 1987, Thrombosis and Haemostasis.

[89]  M. Alessi,et al.  Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. , 1986, Metabolism: clinical and experimental.

[90]  D. Vaughan.  Angiotensin and vascular fibrinolytic balance. , 2002, American journal of hypertension.

[91]  N. Hacohen,et al.  Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. , 2002, Diabetes.

[92]  Haiyan Xu,et al.  Exclusive action of transmembrane TNF alpha in adipose tissue leads to reduced adipose mass and local but not systemic insulin resistance. , 2002, Endocrinology.

[93]  S. Yusuf,et al.  Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. , 2000 .

[94]  G. Reaven.  Syndrome X: 10 years after. , 1999, Drugs.

[95]  A. Hamsten,et al.  Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals , 1998, Diabetologia.

[96]  G. Siest,et al.  Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[97]  B. Spiegelman,et al.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.